

activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 23, 1996.

A. Federal Reserve Bank of Philadelphia (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105:

1. *Collective Bancorp, Inc.*, Cologne, New Jersey; to become a bank holding company by acquiring 100 percent of the voting shares of Continental Bancorporation, Laurel Springs, New Jersey, and thereby indirectly acquire Continental Bank of New Jersey, Laurel Springs, New Jersey.

In connection with this application Collective Bancorp, Inc., has applied to acquire Collective Bank, Egg Harbor, New Jersey, and thereby engage in operating a savings association pursuant to § 225.25(b)(9) of the Board's Regulation Y; Collective Mortgage Services, Inc., Egg Harbor, New Jersey, and thereby engage in making and servicing loans pursuant to § 225.25(b)(1) of the Board's Regulation Y; Collective Financial Services, Egg Harbor, New Jersey, and thereby engage in securities brokerage activities and insurance agency activities in a town of less than 5,000 and underwriting activities pursuant to §§ 225.25(b)(15) and 225.25(b)(8)(iii) & (i) of the Board's Regulation Y.

B. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. *Norwest Corporation*, Minneapolis, Minnesota; to acquire 100 percent of the voting shares of American Bank Moorhead, Moorhead, Minnesota.

Board of Governors of the Federal Reserve System, July 25, 1996.

Jennifer J. Johnson

*Deputy Secretary of the Board*

[FR Doc. 96-19352 Filed 7-30-96; 8:45 am]

BILLING CODE 6210-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Notice of Interest Rate on Overdue Debts

Section 30.13 of the Department of Health and Human Services' claims collection regulations (45 CFR Part 30) provides that the Secretary shall charge an annual rate of interest as fixed by the Secretary of the Treasury after taking

into consideration private consumer rates of interest prevailing on the date that HHS becomes entitled to recovery. The rate generally cannot be lower than the Department of Treasury's current value of funds rate or the applicable rate determined from the "Schedule of Certified Interest Rates with Range of Maturities." This rate may be revised quarterly by the Secretary of the Treasury and shall be published quarterly by the Department of Health and Human Services in the Federal Register.

The Secretary of the Treasury has certified a rate of 13½% for the quarter ended June 30, 1996. This interest rate will remain in effect until such time as the Secretary of the Treasury notifies HHS of any change.

Dated: July 23, 1996.

George Strader,

*Deputy Assistant Secretary, Finance.*

[FR Doc. 96-19491 Filed 7-30-96; 8:45 am]

BILLING CODE 4150-04-M

### Agency for Health Care Policy and Research

#### Health Care Policy and Research Special Emphasis Panel Meeting

In accordance with section 10(a) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2) announcement is made of the following special emphasis panel scheduled to meet during the month of August 1996:

*Name:* Health Care Policy and Research Special Emphasis Panel.

*Date and Time:* August 20, 1996, 8 a.m.

*Place:* Key Bridge Marriott, 1401 Lee Highway, Conference Room TBA, Arlington, Virginia 22209.

Open August 20, 8 a.m. to 8:15 a.m.

Closed for remainder of meeting.

*Purpose:* This Panel is charged with conducting the initial review of grant applications proposing to design and conduct collaborative, multisite, randomized controlled trials to compare the effectiveness and outcomes of hysterectomy to those of other common treatments for non-cancerous uterine conditions.

*Agenda:* The open session of the meeting on August 20, from 8 a.m. to 8:15 a.m., will be devoted to a business meeting covering administrative matters. During the closed session, the panel will be reviewing and discussing grant applications dealing with health services research issues. In accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C. 552b(c)(6), the Administrator, AHCP, has made a formal determination that this latter session will be closed because the discussions are likely to include personal information concerning individuals associated with the grant applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a roster of members or other relevant information should contact Linda Blankenbaker, Agency for Health Care Policy and Research, Suite 400, 2101 East Jefferson Street, Rockville, Maryland 20852, Telephone (301) 594-1437 x1603.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: July 25, 1996.

Clifton R. Gaus,

*Administrator.*

[FR Doc. 96-19506 Filed 7-30-96; 8:45 am]

BILLING CODE 4160-90-M

### Food and Drug Administration

[Docket No. 96M-0254]

#### CIBA Vision Corp.; Premarket Approval of SOLO-care brand MULTI-PURPOSE SOLUTION

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing its approval of the application by CIBA Vision Corp., Duluth, GA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of SOLO-care brand MULTI-PURPOSE SOLUTION. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of April 25, 1996, of the approval of the application.

**DATES:** Petitions for administrative review by August 30, 1996.

**ADDRESSES:** Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** James F. Saviola, Center for Devices and Radiological Health (HFZ-460), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1744.

**SUPPLEMENTARY INFORMATION:** On December 22, 1994, CIBA Vision Corp., Duluth, GA 30136-1518, submitted to CDRH an application for premarket approval of the SOLO-care brand MULTI-PURPOSE SOLUTION. The device is a cleaning, rinsing, disinfecting, and storing solution and is indicated for cleaning, rinsing, disinfecting, and storing soft (hydrophilic) contact lenses and for dissolving enzyme tablets.

In accordance with the provisions of section 515(c)(2) of the act (21 U.S.C.